Aphaia Pharma to Participate in a Panel Discussion at the 10th LSX World Congress
ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 –
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10th LSX World Congress, taking place April 29-30, 2024 in London, England.